Targeted therapies to join chemo as oncology treatment backbone [Yahoo! Finance]
Candel Therapeutics, Inc. (CADL)
Company Research
Source: Yahoo! Finance
treatment towards the use of regimens incorporating targeted therapies. This trend has seen several new drugs become embedded into treatment paradigms across haematological cancers and solid tumours. This shift is, in part, driven by the cytotoxicity associated with chemotherapy, which can have a significant impact on a patient's quality of life (QoL), as well as their ability to tolerate further treatment if they were to relapse. In terms of sales and uptake of targeted therapies, immune checkpoint inhibitors (ICIs) are arguably one of the greatest success stories. This is evidenced by the broad use of MSD's Keytruda (pembrolizumab) across more than 40 cancer indications, as well as its 2025 sales of $31.7bn – making it one of the best-selling drugs currently on the market. Antibody-drug conjugates (ADCs), monoclonal antibodies (mAbs), kinase inhibitors, chimeric antigen receptor T-cell (CAR-T) therapies and radiopharmaceuticals are also making their mark on the space. More tar
Show less
Read more
Impact Snapshot
Event Time:
CADL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CADL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CADL alerts
High impacting Candel Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
CADL
News
- Candel Therapeutics (CADL) had its price target lowered by Citigroup Inc. from $24.00 to $22.00. They now have a "buy" rating on the stock.MarketBeat
- Candel Therapeutics (CADL) had its "buy" rating reaffirmed by Canaccord Genuity Group Inc.. They now have a $25.00 price target on the stock.MarketBeat
- Candel Therapeutics strengthens balance sheet as lead cancer therapy advances [Yahoo! Finance]Yahoo! Finance
- Candel Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate HighlightsGlobeNewswire
- Candel Therapeutics (CADL) was upgraded by Zacks Research from "strong sell" to "hold".MarketBeat
CADL
Earnings
- 3/12/26 - Miss
CADL
Sec Filings
- 3/12/26 - Form S-8
- 3/12/26 - Form 10-K
- 3/12/26 - Form 8-K
- CADL's page on the SEC website